GlassScriptPhysician profile
Alvin Payne
NPI 1427056894
$3,488.18
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $869 · 2021: $1,018 · 2022: $465 · 2023: $305 · 2024: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $513.03 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $393.62 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.59 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $290.81 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $238.35 | 2019-2022 | |
| Novo Nordisk INC | $170.42 | 2019-2020 | |
| Abbott Laboratories | $166.33 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $157.39 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $136.77 | 2019-2022 | |
| Pfizer INC. | $125.45 | 2019-2022 | |
| Allergan, INC. | $121.62 | 2019-2020 | |
| Amgen INC. | $112.72 | 2019-2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $104.74 | 2019-2023 | |
| Esperion Therapeutics, INC. | $79.01 | 2020-2024 | Nexletol |
| Medtronic, INC. | $64.45 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.49 | 2020-2022 | |
| Mannkind Corporation | $59.40 | 2022 | |
| Paratek Pharmaceuticals, INC. | $56.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.72 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $40.88 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.23 | 2019 | |
| Mylan Specialty L.P. | $21.58 | 2020 | |
| Astellas Pharma US INC | $16.49 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.44 | 2024 | Voquezna |
| Eisai INC. | $15.62 | 2024 | |
| Medtronic Minimed, INC. | $15.35 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.68 | 2023 | Gvoke Hypopen |
| Arbor Pharmaceuticals, INC. | $14.61 | 2021 | |
| Irhythm Technologies, INC. | $14.45 | 2023 | Zio Xt Patch |
| Horizon Therapeutics Plc | $13.19 | 2021 | |
| Bardy Diagnostics, INC. | $10.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.